Tofacitinib mechanism of action
Tofacitinib is a medication used to treat certain autoimmune diseases, primarily rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. Its mechanism of action involves targeting specific molecules and pathways in the immune system to reduce inflammation and modulate the immune response. Here's an overview of how tofacitinib works:
Janus Kinase (JAK) Inhibition: Tofacitinib drug belongs to a class of known as Janus Kinase (JAK) inhibitors. JAKs are enzymes that play a crucial role in transmitting signals within immune cells. By inhibiting specific JAK enzymes, tofacitinib interferes with the signaling pathways that lead to inflammation and immune system activation.
Cytokine Inhibition: JAK enzymes are involved in the signaling of various cytokines, which are small proteins that regulate immune responses. Tofacitinib primarily inhibits JAK1 and JAK3, which are associated with signaling by cytokines like interleukin-6 (IL-6), interleukin-2 (IL-2), interleukin-4 (IL-4), interleukin-7 (IL-7), interleukin-15 (IL-15), and interferon-gamma (IFN-gamma). By blocking these cytokine signals, tofacitinib helps reduce inflammation and control immune system activity.
Immune System Modulation: Tofacitinib helps modulate the immune response by reducing the activity of certain immune cells, particularly T cells and B cells, which are involved in autoimmune diseases. It can also affect other immune cells like natural killer (NK) cells and dendritic cells.